Trial Profile
Fecal Biomarker Study for Patients From a Once Daily Study for Efficacy in a Ulcerative Colitis Maintenance Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Mesalazine (Primary)
- Indications Ulcerative colitis
- Focus Biomarker; Pharmacodynamics
- Sponsors Procter & Gamble
- 11 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Oct 2009 New trial record.